Pure Global

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease - Trial NCT06400589

Access comprehensive clinical trial information for NCT06400589 through Pure Global AI's free database. This Phase 3 trial is sponsored by HanAll BioPharma Co., Ltd. and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 750 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06400589
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06400589
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
A Phase 3, Multicenter, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% and 1.0% Compared to Vehicle in Participants With Dry Eye Disease (VELOS-4)

Study Focus

Dry Eye

tanfanercept

Interventional

drug

Sponsor & Location

HanAll BioPharma Co., Ltd.

Delray Beach, United States of America

Timeline & Enrollment

Phase 3

May 01, 2024

Aug 01, 2025

750 participants

Primary Outcome

Schirmer Test

Summary

The objectives of this study are to compare the efficacy and safety of tanfanercept
 ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.

ICD-10 Classifications

Ocular pain
Avulsion of eye
Other corneal deformities
Corneal ulcer
Dry mouth, unspecified

Data Source

ClinicalTrials.gov

NCT06400589

Non-Device Trial